Clinical trial
Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV)…
NCT00423046 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00423046 |
|---|---|
| Title | Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age |
| Official title | Phase IIIb, Observer-blind Study to Compare Immunogenicity of GSK Biologicals' HPV-16/18 L1/AS04 Vaccine Versus Gardasil® [Quadrivalent Human Papillomavirus (HPV-6,11,16,18 L1 VLP) Recombinant Vaccine Merck & Co., Inc.] |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infections, Papillomavirus, Papillomavirus Vaccines |
| Intervention type | Biological |
| Interventions | GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM), Gardasil ® (Merck & Co. Inc), Placebo |
| Enrollment | 1,106 |
| Start date | Jan 24, 2007 |
| Primary completion | Mar 7, 2008 |
| Completion | May 14, 2012 |
| First posted | Jan 17, 2007 |
| Last update posted | Jan 2, 2020 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: